Cancer is a worldwide problem and its incidence is increasing year by year, which severely endangers the human health and lives. In 2008, the world has more than 12 million new cases of cancer and by 2030, this figure will be over 25 million[@b1][@b2]. Until now, the pathogenesis of cancer has not been clarified. A majority of studies suggest it may contribute to the cooperation of environmental factors, genetic susceptibility and acquired susceptibility. And, what is noteworthy is that part of the cancer susceptibility comes from human genome diversity[@b3].

As genome-wide association studies (GWASs) strategy is putting forward, gene mutations or susceptibility loci have been identified for many diseases. To date, more than 50 GWASs focused on cancer have been published, comprising at least 15 different kinds of malignant tumors[@b4]. In 2010, Abnet et al firstly performed a GWAS of gastric cancer (GC) and esophageal squamous cell carcinoma (ESCC) in Chinese populations and identified variants located in the *PLCE1* gene at chromosome 10q23 had a genome-wide significantly correlation with gastric cardia cancer (GCA) and ESCC[@b5]. At the same period, Wang et al also found two susceptibility genes, *PLCE1* and *C20orf54*, were associated with risk of ESCC and GCA for Chinese subjects in another large-scale GWAS[@b6]. Later, Wu et al further confirmed seven single nucleotide polymorphisms (SNPs) at five regions significantly associated with ESCC, among which is *PLCE1* rs2274223 that has also been found in the former two GWASs[@b7].

Rs2274223, located in the 26th exon of the *PLCE1* gene, is a non-synonymous SNP that can cause the amino acid change from histidine to arginine[@b6]. Since three related GWASs were completed, SNP rs2274223 in *PLCE1* became one of the most studied polymorphic loci. A growing number of studies have been conducted to verify its association with kinds of cancer risk. However, the findings were inconsistent. The discrepancies among these studies might attribute to the relatively small sample size in each research and ethnic variation. Therefore, we performed a meta-analysis of all eligible case-control studies to systematically estimate the effects of *PLCE1* rs2274223 A \> G polymorphism on the susceptibility to cancer.

Results
=======

Characteristics of eligible publications
----------------------------------------

A total of 17 eligible articles were identified in the final meta-analysis, which contained 22 studies and involved 13188 cases and 14666 controls. The study selection process was shown in [Figure 1](#f1){ref-type="fig"}[@b8][@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24].

Among the 22 studies, six studies reported on GC with 6813 cases and 5666 controls, and nine studies reported on ESCC with 3348 cases and 5309 controls. In the rest of the studies, there were two studies on esophageal adenocarcinoma (EAC), two studies on colorectal cancer, one study on head and neck cancer (HNC), one study on squamous cell carcinoma of head and neck (SCCHN) and one study on gallbladder cancer (GBC). All studies follow the Hardy-Weinberg equilibrium (HWE) except three studies which derived from Palmer\'s article[@b15]. In addition, there were eight studies for Caucasian population, 12 studies for Chinese population, one study for African population and one study for mixed population. The main characteristics of those studies are listed in [Table 1](#t1){ref-type="table"}.

Results of meta-analysis
------------------------

The associations of *PLCE1* rs2274223 polymorphism with the risk of different types of cancer were shown in [Table 2](#t2){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}. Overall, statistically significant associations were observed among all of the genetic models (G vs. A: OR = 1.15, 95% CI = 1.06--1.25; GG vs. AA: OR = 1.30, 95% CI = 1.10--1.55; GA vs. AA: OR = 1.18, 95% CI = 1.08--1.30; GG/GA vs. AA: OR = 1.20, 95% CI = 1.08--1.32; GG vs. GA/AA: OR = 1.22, 95% CI = 1.04--1.42). Further analysis showed the polymorphism was significantly associated with an increased risk of ESCC other than GC in all genetic models, among which the most obvious is for homozygous model (GG vs. AA: OR = 1.55, 95% CI = 1.17--2.06) and weakest for heterozygous model (GA vs. AA: OR = 1.27, 95% CI = 1.09--1.47).

In GC, stratification analysis by genotyping methods showed that rs2274223 was significantly associated with the risk of GC using TaqMan (G vs. A: OR = 1.20, 95% CI = 1.04--1.39; GA vs. AA: OR = 1.27, 95% CI = 1.12--1.44; GG/GA vs. AA: OR = 1.28, 95% CI = 1.10--1.49). No significant association was detected in the subgroup analysis by ethnicity, source of control, sample size and HWE in controls ([Table 3](#t3){ref-type="table"}).

In ESCC, significantly increased ESCC risk was only discovered for Asian subgroup (G vs. A: OR = 1.44, 95% CI = 1.25--1.66; GG vs. AA: OR = 2.04, 95% CI = 1.47--2.85; GA vs. AA: OR = 1.39, 95% CI = 1.24--1.56; GG/GA vs. AA: OR = 1.49, 95% CI = 1.29--1.72; GG vs. GA/AA: OR = 1.76, 95% CI = 1.31--2.36), but not for Caucasians and other ethnicities. In the stratified analysis by source of control, significant association was only found for hospital-based controls (G vs. A: OR = 1.29, 95% CI = 1.19--1.41; GG vs. AA: OR = 1.61, 95% CI = 1.29--2.03; GA vs. AA: OR = 1.33, 95% CI = 1.18--1.49; GG/GA vs. AA: OR = 1.37, 95% CI = 1.23--1.53; GG vs. GA/AA: OR = 1.42, 95% CI = 1.13--1.77). When stratified by sample size, we observed a significantly increased risk of ESCC in large sample size whose number was more than 1000 (G vs. A: OR = 1.20, 95% CI = 1.09--1.32; GG vs. AA: OR = 1.34, 95% CI = 1.10--1.64; GA vs. AA: OR = 1.26, 95% CI = 1.12--1.41; GG/GA vs. AA: OR = 1.28, 95% CI = 1.14--1.43). We also performed stratification analysis by quality score, significant association was only identified in high score (G vs. A: OR = 1.22, 95% CI = 1.05--1.41; GG vs. AA: OR = 1.46, 95% CI = 1.10--1.93; GA vs. AA: OR = 1.25, 95% CI = 1.06--1.47; GG/GA vs. AA: OR = 1.27, 95% CI = 1.06--1.52; GG vs. GA/AA: OR = 1.32, 95% CI = 1.05--1.65). Furthermore, in the stratified analysis by HWE in controls, we found a significant increased association between *PLCE1* rs2274223 polymorphism and ESCC risk in the studies consistent with HWE (G vs. A: OR = 1.29, 95% CI = 1.13--1.47; GG vs. AA: OR = 1.62, 95% CI = 1.21--2.15; GA vs. AA: OR = 1.32, 95% CI = 1.19--1.46; GG/GA vs. AA: OR = 1.37, 95% CI = 1.20--1.56; GG vs. GA/AA: OR = 1.42, 95% CI = 1.10--1.83) ([Table 3](#t3){ref-type="table"}).

Heterogeneity and sensitivity analysis
--------------------------------------

We observed substantial heterogeneities among all investigations (GG vs. AA: *P* = 0.000; GA vs. AA: *P* = 0.000; GG/GA vs. AA: *P* = 0.000; GG vs. GA/AA: and G vs. A: *P* = 0.001) ([Table 2](#t2){ref-type="table"}). The meta-regression analysis yielded no significant difference between subgroup analysis ([Supplemental Table 1](#s1){ref-type="supplementary-material"}). We further conducted sensitivity analyses to estimate the influence of each individual data on the combined ORs and no significant differences were observed in all genetic models ([Supplemental Figure 1](#s1){ref-type="supplementary-material"}).

Publication bias
----------------

We performed Begg\'s funnel plot and Egger\'s test to assess the publication bias. The shape of the Begg\'s funnel plot showed basically symmetric distribution. The results of Egger\'s test were as follows: G vs. A: t = −0.20, *P* = 0.846; GG vs. AA: t = −0.55, *P* = 0.586; GA vs. AA: t = 0.22, *P* = 0.831; GG/GA vs. AA: t = −0.02, *P* = 0.983 and GG vs. GA/AA: t = −0.56, *P* = 0.580, which further provided no evidence of publication bias ([Figure 3](#f3){ref-type="fig"}).

Discussion
==========

In the meta-analysis, we comprehensively evaluate the association between *PLCE1* rs2274223 polymorphism and cancer risk through 22 studies with 13188 cases and 14666 controls. We observed the genetic variation significantly increased the risk of overall cancer, especially for ESCC. We also found the associations existed in the subgroups of Asian ethnicity, sample size \> 1000, high quality score and the studies consistent with HWE in ESCC.

The *PLCE1* gene is located on chromosome 10q23, encoding PLCE1 protein which is a member of phosphoinositide-specific phospholipase C (PLC). PLCE1 protein, like other PLC families, is composed of the PLC catalytic domain, PH domain, EF domain and C2 domain. In addition, PLCE1 protein also has unique regions, two RA domains at its C terminus and a CDC25-like domain at its N terminus. Especially, the former directly interact with several Ras family GTPases, such as oncogenic KRas and HRas. Therefore, PLCE1, as a multifunctional signaling protein, plays an important role in cell growth, differentiation and oncogenesis[@b25][@b26][@b27]. Simultaneously, an increasing amount of studies start to investigate the association of *PLCE1* rs2274223 polymorphism on the susceptibility of different cancer.

To our knowledge, *PLCE1* mutation is closely associated with many diseases, such as nephrotic syndrome[@b28] and cardiac hypertrophy[@b29]. Although the *PLCE1* rs2274223 polymorphism is associated with a high risk of cancers, the exact mechanism is still unknown. Some studies suggest that PLCE1 protein plays a crucial role in the process of information transmission between the cell membrane and the nucleus. And it probably through augmenting angiogenesis and inflammation, two distinct mechanisms, acts on intestinal tumorigenesis[@b30][@b31]. Furthermore, the research of gene-gene, gene-environmental interactions may provide some important information. However, the Song\'s study[@b32] indicated that smoking, drinking, and Body Mass Index (BMI) did not significantly change the effect of rs2274223 polymorphism in Chinese population.

Two previously meta-analyses[@b33][@b34] have investigated the association between *PLCE1* rs2274223 and different kinds of cancer. Both of them demonstrated that the polymorphism increased the risk of cancer in the pooling analysis, which was the same with ours. In the stratification analysis, the former publication[@b33] showed that *PLCE1* rs2274223 polymorphism contributed to the high risk of esophageal and gastric cancer in Asians. However, in the present study, we observed an increased association in Asian ethnicity only for ESCC other than GC. The discrepancy may result from three reasons as the follows: First of all, we classified esophageal cancer into ESCC and EAC for the reason that genetic variation may have different effect on different pathological type of cancer. Because of a limited number of published studies for EAC, we failed to perform further stratification analysis. Therefore, the association between the *PLCE1* rs2274223 polymorphism and EAC risk was ambiguous. Secondly, the positive result about GC might be attributed to small sample size, when we increased the number more than half, we failed to find the significant association. Moreover, the former study mistakenly put the northern Indian population into Asians which may make the result bias. The latter study[@b34] identified *PLCE1* rs2274223 polymorphism was associated with the risk of upper aerodigestive tract cancer (ESCC, EC, HNC and SCCHN) but not with gastric and colorectal cancer. However, we did not combine the HNC, SCCHN, EAC and colorectal cancer, because it might be more appropriate to show the results without meta-analysis when the number of studies was less than three.

Compared with the previous publications, our meta-analysis has advantages. Above all, this is by far an analysis with the largest sample size which provided a power of above of 80% investigating the association. What is more, among all the included studies, 95.45% (21/22) were considered as high quality. Furthermore, sensitivity analysis revealed no significant influence of a single study on the summary ORs or the 95% CI. Additionally, no obvious evidence of publication bias existed, which indicated that the result may be unbiased. Some studies have discovered some sequence variants in the region of chromosome, such as 5p15.33 and 8q24, are associated with risk of different cancer types[@b35][@b36][@b37][@b38][@b39], so we speculated that rs2274223 may be the specific site associated with different cancer types. However, in the further subgroup analyses, we found rs2274223 significantly associated with an increased risk of ESCC rather than GC which suggested it has no non-specific effect on different types of cancer. So, it appropriate or not to calculate the association of genetic variation with the risk of cancer by pooling the data from different type of cancer remains open to question although researchers have always done this way. Additionally, further functional studies should be carried out to explore the mechanism underlying the variant-related associations with cancer risk.

There was substantial between-study heterogeneity in the meta-analysis. So, although the statistical evidence proved the findings to be reliable, we did not deem lightly of the issue. We used random-effects model to incorporate heterogeneity among studies. However, random-effects model is not a substitute for a thorough investigation of heterogeneity. In addition, we performed the analysis with strict criteria for study inclusion, carried out meta-regression but found no source of heterogeneities. However, further stratification analysis demonstrated that cancer type, source of control and sample size may be the main source of heterogeneities. Besides, there is other heterogeneity that cannot be explained.

Some other limitations should be acknowledged. Firstly, although we had enrolled 22 studies, the sample size for certain cancer types and ethnicities remained relatively small that we could not perform further subgroup analyses. Secondly, we failed to conduct the adjusted estimates for unavailable original data, such as age, sex, smoking and drinking status et al which could make the result masked. Thirdly, some studies are hospital-based design which would not represent the people who live in a certain region. Lastly, even though there is no statistical evidence of publication bias, we may miss some unpublished investigations showing no significant effect or publications written in other languages. Additionally, the power of the funnel plot to test the asymmetry is relatively low when studies were less than 30 or smaller studies were lower methodological quality. What is more, most of the data are retrospective in the meta-analysis. Therefore, reporting publication bias from prospective studies is needed.

In conclusion, the meta-analysis suggests that *PLCE1* rs2274223 polymorphism may be associated with increased susceptibility to cancer, especially for ESCC. However, due to the limitations of the meta-analysis, the conclusion might be not conclusive which need more studies with larger sample size and appropriate design to confirm.

Methods
=======

Publication searching
---------------------

We identified publications from PubMed and The New England Journal of Medicine (OVID platform) using the following search items: "PLCE1" or "Phospholipase C epsilon 1" "SNP" or "polymorphism" or \"variant\", and "cancer" or \"carcinoma\" or \"neoplasm\" or \"malignance\". We also identified related publications written in Chinese from China National Knowledge Infrastructure (CNKI) and WanFang database using the combinations terms of "PLCE1" or "Phospholipase C epsilon 1" "SNP" or "polymorphism" or \"variant\", and "cancer" or \"carcinoma\" in Chinese. The languages were limited to English and Chinese. We further screened the whole references with the date up to April 2014 and confirmed potential relevant studies according to the title and abstract.

Selection criteria
------------------

All studies included in the meta-analysis are accorded with the following inclusion criteria: (a). Full text available; (b). Study focus on the association of *PLCE1* rs2274223 polymorphism and cancer susceptibility; (c). Case-control studies; (d). Genotype data available. In addition, exclusion criteria were as follows: (a). Overlapped articles or repeated studies; (b). Review articles, dissertations and conference reports.

Data extraction
---------------

Two researchers independently extracted data from each eligible study with the following items: the first author, year of publication, the type of cancer, country, ethnicity, source of controls, genotyping technology, number of cases and controls, the quantity of each genotype in cases and controls, Minor Allele Frequency (MAF) and value of HWE. In order to ensure the accuracy of the data, when encountering inconsistent, we discussed together to reach a consensus.

Quality assessment
------------------

According to the quality assessment criteria ([Supplemental Table 2](#s1){ref-type="supplementary-material"}), we assessed the quality of each study. Quality scores of studies ranged from 0 (lowest) to 15 (highest). Studies which scores less than 9 were categorized into low quality, while those scores equal to or greater than 9 were regarded as high quality[@b40].

Data analysis
-------------

STATA software (version 11.0; Stata Corporation, College Station, TX) was used to perform all analyses. We used allelic (G vs. A), homozygote (GG vs. AA), heterozygote (GA vs. AA), dominant (GG/GA vs. AA) and recessive (GG vs. GA/AA) as the models. The genetic association between the *PLCE1* rs2274223 polymorphism and the risk of cancer was evaluated by the pooled odds ratios (OR) and 95% confidence interval (CI). If the *P* value of the Z test was less than 0.05, we considered the pooled OR statistically significant. Heterogeneity was analyzed using the Chi-squared-based Q-test. When there existed significant heterogeneity (*P* \< 0.10), the random-effects model was used[@b41]. Otherwise, the fixed effects model was used[@b42]. Stratification and meta-regression analyses were conducted to explore the potential source of heterogeneity across studies. We also performed stratified analyses by cancer type (ESCC and GC), ethnicity (Asian and Caucasian), control source (hospital-based and population-based), quality score of studies (low and high), sample size (\>1000 and ≤1000), Genotyping methods (TaqMan and others) and HWE. Sensitivity analyses were performed to measure the stability of the results when one study was removed and the influence of the independent study on the pooled OR at the same time. Publication bias among the literatures was evaluated by Begg\'s funnel plot and Egger\'s test (*P* \< 0.05 was considered significant)[@b43][@b44].
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###### Characteristics of the 17 publications included in this meta-analysis

  Study             Country      Ethnicity   Cancer type   Source of controls   Genotyping methods   Sample sizes(Cases/controls)   HWE (controls)   HWE (cases)   Score
  ------------- --------------- ----------- ------------- -------------------- -------------------- ------------------------------ ---------------- ------------- -------
  Ma,2011             USA        Caucasian      SCCHN              HB                 TaqMan                  1097/1089                 0.977           0.234       12
  Zhang,2011         China         Asian       Gastric             PB                 TaqMan                  1665/1848                 0.451           0.664       14
  Bye,2012       South African    African       ESCC             Mixed                TaqMan                   418/850                  0.886           0.625       11
                 South African     Mixed        ESCC               HB                 TaqMan                   254/857                  0.807           0.522       10
  Gu,2012            China         Asian        ESCC               HB               MassArray                  379/371                  0.457           0.653       10
  Hu,2012            China         Asian        ESCC               HB                 TaqMan                  1061/1211                 0.577           0.975       12
  Li,2012            China         Asian     Colorectal            HB               MassArray                  231/292                  0.089           0.339        9
  Yang,2012          China         Asian       Gastric             HB               MassArray                  249/292                  0.089           0.539        9
  Palmer,2012       Poland       Caucasian     Gastric             PB                 TaqMan                   289/376                  0.307           0.964       10
                      USA        Caucasian     Gastric             PB                 TaqMan                   306/210                  0.039           0.036       10
                      USA        Caucasian      ESCC               PB                 TaqMan                    52/210                  0.039           0.579        9
                      USA        Caucasian       EAC               PB                 TaqMan                   107/210                  0.039           0.834        9
  Wang,2012          China         Asian       Gastric             HB                 TaqMan                  1059/1240                 0.224           0.551       11
  Zhou,2012          China         Asian        ESCC               HB                PCR-LDR                   517/510                  0.646           0.318       11
  Dura,2013       Netherlands    Caucasian      ESCC               PB                 TaqMan                    86/580                  0.950           0.507        9
                  Netherlands    Caucasian       EAC               PB                 TaqMan                   258/580                  0.950           0.554        9
  Duan,2013          China         Asian        ESCC               PB                PCR-RFLP                  381/420                  0.582           0.271       11
  Yuan,2013          China         Asian         HNC               HB                 TaqMan                   501/879                  0.243           0.363       12
  Sharma,2013    North Indian    Caucasian       GBC               HB                PCR-RFLP                  416/225                  0.367           0.000       10
  Chen,2013          China         Asian        ESCC               HB              MALDI-TOF MS                200/300                  0.210           0.895        8
  Wang,2014          China         Asian     Colorectal            HB                 TaqMan                   417/416                  0.454           0.953       10
  Song,2014         Korean         Asian       Gastric             HB                  HRM                    3245/1700                 0.148           0.088       11

SCCHN, squamous cell carcinoma of head and neck; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; HNC, head and neck cancer; GBC, gallbladder cancer; PB, population based; HB, hospital based; HWE, Hardy-Weinberg equilibrium; PCR-LDR, polymerase chain reaction ligase detection reaction; PCR-RFLP, Polymorphism chain reaction-restriction fragment length polymorphism; MALDI-TOF MS, matrix assisted laser desorption ionization/time of flight mass spectrometry; HRM, high-resolution melting.

###### Meta-analysis of the association between *PLCE1* rs2274223 A \> G polymorphism and cancer risk

  Variables                                             G vs. A          GG vs. AA   GA vs. AA       GG/GA vs. AA        GG vs. GA/AA                                                                                                                          
  --------------------------------------------- ----------------------- ----------- ----------- ----------------------- -------------- ------- ----------------------- ------- ------- ----------------------- ------- ------- ----------------------- ------- -------
  All                                            **1.15 (1.06--1.25)**     0.001       0.000     **1.30 (1.10--1.55)**      0.003       0.000   **1.18 (1.08--1.30)**   0.001   0.000   **1.20 (1.08--1.32)**   0.000   0.000   **1.22 (1.04--1.42)**   0.012   0.001
  Cancer Type                                                                                                                                                                                                                                                      
  GC                                               1.11 (0.95--1.31)       0.184       0.000       1.26 (0.94--1.68)        0.118       0.010     1.12 (0.92--1.37)     0.253   0.000     1.14 (0.93--1.39)     0.217   0.000     1.22 (0.96--1.54)     0.100   0.057
  ESCC                                           **1.25 (1.08--1.44)**     0.002       0.000     **1.55 (1.17--2.06)**      0.002       0.015   **1.27 (1.09--1.47)**   0.002   0.034   **1.30 (1.10--1.53)**   0.002   0.004   **1.39 (1.10--1.77)**   0.007   0.059
  EAC                                              1.07 (0.88--1.29)       0.503       0.883       1.17 (0.75--1.81)        0.495       0.474     1.05 (0.81--1.37)     0.707   0.511     1.07 (0.83--1.37)     0.601   0.720     1.14 (0.75--1.74)     0.534   0.333
  Colorectal                                       1.02 (0.53--1.95)       0.948       0.001       0.74 (0.13--4.33)        0.742       0.003     1.17 (0.71--1.92)     0.532   0.038     1.10 (0.58--2.10)     0.760   0.005     0.71 (0.15--3.44)     0.668   0.006
  HNC                                              1.14 (0.95--1.38)       0.167         /         1.70 (1.02--2.86)        0.044         /       1.03 (0.81--1.30)     0.807     /       1.09 (0.87--1.37)     0.430     /       1.69 (1.01--2.81)     0.045     /
  SCCHN                                            1.07 (0.94--1.21)       0.291         /         1.09 (0.81--1.45)        0.580         /       1.13 (0.94--1.35)     0.183     /       1.12 (0.95--1.33)     0.188     /       1.02 (0.78--1.35)     0.878     /
  GBC                                              1.09 (0.85--1.40)       0.512         /         0.52 (0.24--1.12)        0.094         /       1.49 (1.07--2.09)     0.020     /       1.35 (0.98--1.88)     0.068     /       0.42 (0.20--0.89)     0.024     /
  Publication Bias[c](#t2-fn3){ref-type="fn"}                              0.846                                            0.586                                       0.831                                   0.983                                   0.580      

^a^*P* value of the Z-test for odds ration test;

^b^*P* value of the Q-test for heterogeneity test;

^c^P value of Egger\'s test for publication bias; GC, gastric cancer; ESCC, esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; SCCHN, squamous cell carcinoma of head and neck; HNC, head and neck cancer; GBC, gallbladder cancer.

###### Meta-analysis of the association between *PLCE1* rs2274223 A \> G polymorphism and different types of cancer (GC and ESCC) risk

  Variables                    G vs. A          GG vs. AA   GA vs. AA       GG/GA vs. AA        GG vs. GA/AA                                                                                                                          
  -------------------- ----------------------- ----------- ----------- ----------------------- -------------- ------- ----------------------- ------- ------- ----------------------- ------- ------- ----------------------- ------- -------
  GC                      1.11 (0.95--1.31)       0.184       0.000       1.26 (0.94--1.68)        0.118       0.010     1.12 (0.92--1.37)     0.253   0.000     1.14 (0.93--1.39)     0.217   0.000     1.22 (0.96--1.54)     0.100   0.057
  Ethnicity                                                                                                                                                                                                                               
   Asian                  1.15 (0.94--1.42)       0.180       0.000       1.34 (0.92--1.95)        0.127       0.004     1.15 (0.89--1.48)     0.278   0.000     1.17 (0,90--1.52)     0.228   0.000     1.29 (0.96--1.74)     0.096   0.031
   Caucasian              1.03 (0.87--1.22)       0.732       0.409       1.06 (0.72--1.55)        0.772       0.623     1.06 (0.81--1.38)     0.679   0.287     1.05 (0.82--1.35)     0.682   0.293     1.01 (0.70--1.44)     0.967   0.879
  Source of control                                                                                                                                                                                                                       
   PB                     1.15 (0,91--1.47)       0.237       0.011       1.37 (0.81--2.33)        0.241       0.019     1.19 (0.97--1.47)     0.097   0.157     1.20 (0.93--1.55)     0.161   0.056     1.29 (0.81--2.06)     0.288   0.030
   HB                     1.07 (0.88--1.32)       0.487       0.005       1.13 (0.93--1.37)        0.233       0.511     1.09 (0.79--1.50)     0.601   0.000     1.09 (0,81--1.47)     0.561   0.001     1.13 (0.93--1.37)     0.211   0.723
  Genotyping methods                                                                                                                                                                                                                      
   TaqMan               **1.20 (1.04--1.39)**     0.015       0.029       1.39 (0.97--2.00)        0.073       0.033   **1.27 (1.12--1.44)**   0.000   0.254   **1.28 (1.10--1.49)**   0.001   0.122     1.28 (0.92--1.78)     0.135   0.049
   MassArray              1.03 (0.77--1.37)       0.848         /         0.91 (0.45--1.83)        0.783         /       1.12 (0.77--1.61)     0.556     /       1.08 (0.76--1.52)     0.668     /       0.87 (0.44--1.74)     0.698     /
   HRM                    0.96 (0.87--1.05)       0.342         /         1.07 (0.84--1.37)        0.561         /       0.88 (0.77--0.99)     0.034     /       0.90 (0.80--1.01)     0.086     /       1.14 (0.90--1.44)     0.293     /
  Sample size                                                                                                                                                                                                                             
   \>1000                 1.18 (0.93--1.51)       0.173       0.000       1.44 (0.95--2.20)        0.090       0.002     1.16 (0.86--1.57)     0.333   0.000     1.20 (0.88--1.63)     0.250   0.000     1.37 (0.99--1.89)     0.059   0.025
   ≤1000                  1.03 (0.89--1.19)       0.695       0.711       1.02 (0.73--1.43)        0.902       0.824     1.08 (0.88--1.32)     0.481   0.552     1.06 (0.87--1.29)     0.543   0.572     0.98 (0.71--1.34)     0.887   0.925
  HWE                                                                                                                                                                                                                                     
   Yes                    1.14 (0.96--1.36)       0.136       0.000       1.30 (0.96--1.78)        0.095       0.007     1.16 (0.93--1,44)     0.190   0.000     1.17 (0.94--1.47)     0.158   0.000     1.24 (0.96--1.60)     0.096   0.040
   No                     0.95 (0.73--1.23)       0.682         /         0.92 (0.47--1.81)        0.809         /       0.91 (0.63--1.32)     0.629     /       0.91 (0.64--1.31)     0.622     /       0.97 (0.51--1.85)     0.917     /
  ESCC                  **1.25 (1.08--1.44)**     0.002       0.000     **1.55 (1.17--2.06)**      0.002       0.015   **1.27 (1.09--1.47)**   0.002   0.034   **1.30 (1.10--1.53)**   0.002   0.004   **1.39 (1.10--1.77)**   0.007   0.059
  Ethnicity                                                                                                                                                                                                                               
   Asian                **1.44 (1,25--1.66)**     0.000       0.059     **2.04 (1.47--2.85)**      0.000       0.119   **1.39 (1.24--1.56)**   0.000   0.471   **1.49 (1.29--1.72)**   0.000   0.182   **1.76 (1.31--2.36)**   0.000   0.195
   Caucasian              0.82 (0.59--1.13)       0.225       0.264       0.71 (0.35--1.46)        0.354       0.905     0.73 (0.35--1.51)     0.393   0.067     0.73 (0.39--1.37)     0.323   0.097     0.80 (0.40--1.61)     0.539   0.723
   African                1.06 (0.89--1.25)       0.521         /         1.10 (0.78--1.57)        0.587         /       1.09 (0.84--1.42)     0.510     /       1.09 (0.85--1.40)     0.474     /       1.05 (0.76--1.43)     0.776     /
   Mixed                  1.16 (0.95--1.42)       0.139         /         1.32 (0.87--1.99)        0.196         /       1.27 (0.92--1.74)     0.145     /       1.28 (0.95--1.73)     0.109     /       1.14 (0.79--1.65)     0.478     /
  Source of control                                                                                                                                                                                                                       
   PB                     1.07 (0.57--2.02)       0.828       0.000       1.28 (0.39--4.14)        0.683       0.004     1.00 (0.50--2.03)     0,992   0.001     1.03 (0.48--2.21)     0.942   0.000     1.33 (0.52--3.38)     0.552   0.027
   HB                   **1.29 (1.19--1.41)**     0.000       0.496     **1.61 (1.29--2.03)**      0.000       0.365   **1.33 (1.18--1.49)**   0.000   0.950   **1.37 (1.23--1.53)**   0.000   0.829   **1.42 (1.13--1.77)**   0.002   0.338
   Mixed                  1.06 (0.89--1.25)       0.521         /         1.10 (0.7--1.57)         0.587         /       1.09 (0.84--1.42)     0.510     /       1.09 (0.85--1.40)     0.474     /       1.05 (0.76--1.43)     0.776     /
  Genotyping methods                                                                                                                                                                                                                      
   TaqMan                 1.08 (0.93--1.25)       0.300       0.077       1.22 (0.99--1.50)        0.065       0.464     1.09 (0.88--1.35)     0.417   0.065     1.09 (0.88--1.35)     0.420   0.045     1.13 (0.93--1.36)     0.224   0.712
   MassArray              1.40 (1.10--1.78)       0.006         /         1.82 (0.99--3.33)        0.052         /       1.42 (1.05--1.94)     0.024     /       1.48 (1.11--1.98)     0.008     /       1.59 (0.88--2.88)     0.124     /
   PCR-LDR                1.35 (1.11--1.64)       0.003         /         1.76 (1.06--2.92)        0.029         /       1.39 (1.08--1.80)     0.011     /       1.44 (1.13--1.84)     0.004     /       1.52 (0.93--2.50)     0.096     /
   PCR-RFLP               1.86 (1.48--2.35)       0.000         /         3.46 (1.87--6.38)        0.000         /       1.78 (1.31--2.40)     0.000     /       1.97 (1.48--2.62)     0.000     /       2.80 (1.53--5.11)     0.001     /
   MALDI-TOF MS           1.54 (1.16--2.05)       0.003         /         3.17 (1.45--6.93)        0.004         /       1.39 (0.95--2.02)     0.087     /       1.55 (1.08--2.22)     0.017     /       2.76 (1.28--5.93)     0.009     /
  Sample size                                                                                                                                                                                                                             
   \>1000               **1.20 (1.09--1.32)**     0.000       0.274     **1.34 (1.10--1.64)**      0.004       0.468   **1.26 (1.12--1.41)**   0.000   0.620   **1.28 (1.14--1.43)**   0.000   0.482   **1.20 (1.00--1.45)**   0.050   0.565
   ≤1000                  1.25 (0.92--1.70)       0.146       0.000       1.74 (0.94--3.21)        0.078       0.014     1.21 (0.87--1.69)     0.264   0.006     1.25 (0.87--1.80)     0.220   0.001   **1.67 (1.01--2.75)**   0.046   0.068
  Score                                                                                                                                                                                                                                   
   High                 **1.22 (1.05--1.41)**     0.011       0.000     **1.46 (1.10--1.93)**      0.008       0.034   **1.25 (1.06--1.47)**   0.008   0.021   **1.27 (1.06--1.52)**   0.009   0.003   **1.32 (1.05--1.65)**   0.017   0.125
   Low                    1.54 (1.16--2.05)       0.003         /         3.17 (1.45--6.93)        0.004         /       1.39 (0.95--2.02)     0.087     /       1.55 (1.08--2.22)     0.017             2.76 (1.28--5.93)     0.009     /
  HWE                                                                                                                                                                                                                                     
   Yes                  **1.29 (1.13--1.47)**     0.000       0.003     **1.62 (1.21--2.15)**      0.001       0.016   **1.32 (1.19--1.46)**   0.000   0.367   **1.37 (1.20--1.56)**   0.000   0.071   **1.42 (1.10--1.83)**   0.007   0.040
   No                     0.66 (0.40--1.07)       0.095         /         0.67 (0.21--2.16)        0.508         /       0.48 (0.25--0.92)     0.028     /       0.51 (0.27--0.94)     0.031     /       0.95 (0.30--2.94)     0.924     /

^a^*P* value of the Z-test for odds ration test;

^b^*P* value of the Q-test for heterogeneity test; GC, gastric cancer; ESCC, esophageal squamous cell carcinoma; PB, Population based; HB, Hospital based; PCR-LDR, polymerase chain reaction ligase detection reaction; PCR-RFLP, Polymorphism chain reaction-restriction fragment length polymorphism; MALDI-TOF MS, matrix assisted laser desorption ionization/time of flight mass spectrometry; HRM, high-resolution melting; HWE, Hardy-Weinberg equilibrium.

[^1]: These authors contributed equally to this work.
